Aidan Mohl, 13, will be born on November 11th.
Christopher Aluka Berry | Reuters
Dr. Scott Gottlieb told CNBC on Wednesday it was still possible the Food and Drug Administration will approve Pfizer and BioNTech’s Covid-19 vaccine for young children by Halloween.
“I wouldn’t rule out the possibility that this could come out in October,” said Gottlieb, who sits on Pfizer’s board of directors and served as FDA commissioner in the Trump administration for two years.
Pfizer presented the FDA with initial data on Covid vaccine studies for children ages 5-11 to the FDA on Tuesday, and the company should “shortly” submit a formal application for emergency approval, Gottlieb said in an interview on Wednesday on ” Squawk Box “.
The Food and Drug Administration has a lot of experience with the Pfizer vaccine, noted Gottlieb, adding that the Covid vaccination for young children is the same two-dose regimen as adults, but given in smaller amounts. The agency has already approved the recordings for Americans aged 12 and over.
“You saw a lot of clinical data,” he said. “I’ve said for a long time that October is a possibility, but it’s an optimistic possibility. If it fails, it could fall by mid-November.”
Gottlieb’s comments come a day after the Wall Street Journal reported that regulatory clearance of the Pfizer vaccine for children ages 5-11 may not come before November.
Last week Pfizer released new data showing that in a clinical study in children ages 5-11 years old, a two-dose dose of 10 micrograms – one third of the dose for adolescents and adults – is safe and elicits a “robust” immune response .
Pfizer was expected to apply for emergency approval to use the vaccine in young children by the end of this month, but now the company says it will apply “in the coming weeks”.
That could mean the footage might not be available until November, when the FDA spends as much time reviewing the data for this age group as it does for 12-15 year olds. Pfizer and BioNTech filed for expanded use of their syringe in adolescents on April 9th and were approved by the FDA on May 10th.
A Pfizer spokesman declined to comment on an approval schedule, saying the company couldn’t speculate on exactly when the FDA would make a decision on whether or not to approve the vaccine’s use.
“We are still on track to formally apply for EEA very soon,” Jerica Pitts told CNBC.
Approval couldn’t come sooner as children are starting the new school year, the Delta variant spills across America, and many parents are anxious to get their younger children vaccinated. The exposure has led to an increase in hospital admissions in the United States, including young children who are currently unable to be vaccinated.
Disclosure: Scott Gottlieb is a CNBC employee and a member of the board of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion, and biotechnology company Illumina. He is also co-chair of the Healthy Sail Panel of Norwegian Cruise Line Holdings and Royal Caribbean.